6BIO
| Code | Size | Price |
|---|
| AG-CR1-0056-M001 | 1 mg | £40.00 |
Quantity:
| AG-CR1-0056-M005 | 5 mg | £75.00 |
Quantity:
| AG-CR1-0056-M025 | 25 mg | £270.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
4°C
Documents
Further Information
Alternate Names/Synonyms:
(2?Z,3?E)-6-Bromoindirubin-3?-oxime
Appearance:
Dark red solid.
CAS:
667463-62-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Protect from light.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18,22H,(H,19,21)/b15-13-,20-14+
InChiKey:
DDLZLOKCJHBUHD-WAVHTBQISA-N
Long Description:
Chemical. CAS: 667463-62-9. Formula: C16H10BrN3O2. MW: 356.2. Phosphoinositide-dependent kinase 1 (PDK1) inhibitor. Potent, reversible and ATP-competitive glycogen synthase kinase-3alpha/beta (GSK-3alpha/beta) inhibitor. JAK/STAT3 signaling inhibitor. Apoptosis inducer. Potent antiproliferative agent in malignant lymphoid cell. Antimetastatic agent. Potent chemosensitizing agent fighting TRAIL resistant cancer cells.
MDL:
MFCD08705318
Molecular Formula:
C16H10BrN3O2
Molecular Weight:
356.2
Package Type:
Vial
Precautions:
P261, P271, P280, P312
Product Description:
Phosphoinositide-dependent kinase 1 (PDK1) inhibitor. Potent, reversible and ATP-competitive glycogen synthase kinase-3alpha/beta (GSK-3alpha/beta) inhibitor. JAK/STAT3 signaling inhibitor. Apoptosis inducer. Potent antiproliferative agent in malignant lymphoid cell. Antimetastatic agent. Potent chemosensitizing agent fighting TRAIL resistant cancer cells.
Purity:
>98% (NMR)
Signal word:
Warning
SMILES:
ON=C1C(NC2=CC=CC=C12)=C1C(=O)NC2=C1C=CC(Br)=C2
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
GSK-3-selective inhibitors derived from Tyrian purple indirubins: L. Meijer, et al.; Chem. Biol. 10, 1255 (2003) | Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases: P. Polychronopoulos, et al.; J. Med. Chem. 47, 935 (2004) | The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes: A.S. Tseng, et al.; Chem. Biol. 13, 957 (2006) | 7-Bromoindirubin-3'-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2006) | Inverse in silico screening for identification of kinase inhibitor targets: S. Zahler, et al.; Chem. Biol. 14, 1207 (2007) | An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007) | Indirubin derivatives inhibit malignant lymphoid cell proliferation: A. Chebel, et al.; Leuk. Lymphoma 50, 2049 (2009) | 6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells: L. Liu, et al.; Cancer Res. 71, 3972 (2011) | Indirubin derivative 6BIO suppresses metastasis: S. Braig, et al.; Cancer Res. 73, 6004 (2013) | The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer: S. Braig, et al.; Biochem. Pharmacol. 91, 157 (2014)
Related Products
| Product Name | Product Code | Supplier | 7BIO | AG-MR-C0020 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|